News:

ReNeuron has negotiated a Supplemental Terms Agreement with potential to generate revenue of up to £6m

01 July 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, is pleased to announce that it has negotiated and signed a Supplemental Terms Agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) which has the potential to generate revenues of up to £6m for the Company.

Read more…

20 June 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, will announce its preliminary results for the year ended 31 March 2022 on Monday 4 July 2022.

Read more…

3 May 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that the Company will be attending the International Society of Cell and Gene Therapy Annual Meeting (ISCT 2022) from the 4-7 May in San Francisco, California.

Read more…

22 March 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.

Read more…

22 March 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces the appointment of Liberum Capital Limited as the Company’s Nominated Adviser and Joint Broker with immediate effect.

Read more…

11 February 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Olav Hellebø is standing down as CEO and executive director of the Company and will leave the Company on 28 February 2022.

Read more…

28 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell based Exosome Technologies, announces that it will provide a live presentation and Q&A for investors on Friday 4 February 2022 at 12.00pm (GMT).

Read more…

Priority focus now on Exosome drug delivery technology & Partnerships Ophthalmology assets to be out-licensed

18 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces a strategic update following a review of the latest data from the hRPC (human retinal progenitor cells) Phase 2a clinical trial for retinitis pigmentosa (RP) and an assessment of the commercial potential for its Exosome technology.

Read more…

Progression with Fosun Pharma underscores commitment to CTX stroke disability programme

13 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that following on from the original Fosun Pharma (“Fosun”) licensing agreement announced on 9 April 2019, the Company has signed an additional agreement with Fosun, on 5 January 2022, setting out the first steps in the potential technology transfer of the CTX drug product for the stroke disability programme.

Read more…

11 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.

Read more…